Residual C-peptide secretion is associated with better continuous glucose monitoring (CGM)-metrics in adults with short-lasting type 1 diabetes
Authors' conclusion
C-peptide microsecretion is associated with a low risk of hypoglycemia and improved CGM metrics. Therapeutic approaches aimed at preserving minimal C-peptide secretion could potentially enhance glycemic outcomes and reduce hypoglycemic risk in individual with T1D.
Study context
- Population
- Adults with T1D duration <15 years using CGM
- Participants
- 61 adults
- Exposure
- Time below range (TBR) <3% vs TBR ≥3%
- Low-TBRn = 45
- High-TBRn = 15reference
- Outcome
- Random C-peptide levels by TBR category (hypoglycemia risk)
Methodological detailsadjusted for disease duration
- Adjusted for disease duration
Main finding
As reported in the abstract
Random C-peptide
P = 0.036
Observational data: associations, not effects.
Further findings
C-peptide, all participants
- Median [25th-75th percentiles] C-peptide
- 49.3 [15.7-152] pmol/L
C-peptide and other CGM metrics
- Higher C-peptide associated with better CGM metrics
- P < 0.05
C-peptide cut-off for high hypoglycemia risk
- Best cut-off to distinguish high hypoglycemia risk
- 15.1 pmol/L
Original publication
Residual C-peptide secretion is associated with better CGM-metrics in adults with short-lasting type 1 diabetes. Diabetes Res Clin Pract. Published 23 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →